stockportfolio.pro
DGX vs ONC: Which Stock Is the Better Buy?
Quest Diagnostics Incorporated and BeOne Medicines AG side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — DGX vs ONC, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Quest Diagnostics Incorporated (DGX) | BeOne Medicines AG (ONC) | |
|---|---|---|
| Market cap | $23.9B | $27.0B |
| Revenue (latest FY) | $11.04B | $5.34B |
| Net income (latest FY) | $992.00M | $286.93M |
| Revenue growth (5y CAGR) | 3.2% | 76.8% |
| Net margin | 9.0% | 5.4% |
| Return on equity | 13.8% | 6.6% |
| P/E ratio | 23.8 | 58.8 |
| Dividend yield | 1.6% | — |
| Profitable years (of last 10) | 10 | 1 |
| Positive free cash flow | Yes | Yes |
See the full DGX vs ONC breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open DGX's full financials → Open ONC's full financials →More comparisons
Frequently asked questions
Which is bigger, DGX or ONC?
BeOne Medicines AG is larger by market capitalization — $27.0B versus $23.9B.
Which grows faster, DGX or ONC?
Over the last five fiscal years, BeOne Medicines AG grew revenue faster — 76.8%/yr versus 3.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
DGX fundamentals → · ONC fundamentals → · All 1,500+ companies → · Free screener →